Liquidia Corporation (LQDA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $60.91, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606.
Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH and PH-ILD in May 2025, and promoting Treprostinil Injection (generic parenteral treprostinil) under a profit-sharing arrangement with Sandoz. Revenue is... Read more
Sell if holding. At $60.91, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Liquidia Corporation
Latest news
- Liquidia(LQDA.US) Officer Sells US$3.07 Million in Common Stock - Moomoo — Moomoo negative
- Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock - MarketBeat — MarketBeat negative
- Liquidia CEO Roger Jeffs sells $3.07m in company stock - Investing.com — Investing.com negative
- Liquidia (NASDAQ:LQDA) Raised to "Strong-Buy" at Zacks Research - MarketBeat — MarketBeat positive
- Liquidia (LQDA) Is Up 7.8% After EPS, Revenue Beat Forecasts And Insider 10b5-1 Sales - What's Changed - simplywall.st — simplywall.st positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYUTREPIA10-K Item 1A: 'We are primarily dependent on the success of YUTREPIA, for which we recently received FDA approval for the treatment of PAH and PH-ILD'
- HIGHpipelineL60610-K Item 1A: 'our planned pivotal clinical trial of L606, may not be successful and delays in such preclinical studies or clinical trials may cause our costs to increase'
- HIGHSuppliersingle suppliers for YUTREPIA active ingredient, device, encapsulation and packaging10-K Item 1A: 'single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the drug product and device for L606'
- HIGHcounterpartySandoz10-K Item 1A: 'Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection and is dependent on Sandoz to manufacture and supply Treprostinil Injection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $60.91, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $55.78. Score 5.3/10, moderate confidence.
Take-profit target: $59.34 (-1.1% upside). Prior stop was $55.78. Stop-loss: $55.78.
Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606; Analyst target reached - limited upside remaining.
Liquidia Corporation trades at a P/E of 352.8 (forward 10.8). TrendMatrix value score: 4.6/10. Verdict: Sell.
15 analysts cover LQDA with a consensus score of 4.1/5. Average price target: $65.
What does Liquidia Corporation do?Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH...
Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH and PH-ILD in May 2025, and promoting Treprostinil Injection (generic parenteral treprostinil) under a profit-sharing arrangement with Sandoz. Revenue is derived from YUTREPIA sales and the Sandoz partnership; the company has an accumulated deficit of $626 million and achieved first profitability in Q3/Q4 2025.